
Caravan Biologix is a biotechnology company focused on revolutionizing therapeutics, particularly in oncology and hereditary diseases, by developing novel CAR-directed BioSphere Nanotechnology, also known as Mini-CAR. This technology emulates the functions of immune cells like T cells, NK cells, or macrophages, offering a highly targeted and safe therapeutic agent. Mini-CARs are designed to address the limitations of conventional CAR whole cell therapies, including solid tumor cancers and hereditary diseases. The company's business model includes developing its own pipeline of Mini-CAR drugs and out-licensing its platform technology to other biotech companies. Caravan Biologix leverages AI for CAR design and aims to enhance efficacy, accessibility, and safety, such as by eliminating Cytokine Release Syndrome (CRS). The company is based in Greenwood Village, CO.

Caravan Biologix is a biotechnology company focused on revolutionizing therapeutics, particularly in oncology and hereditary diseases, by developing novel CAR-directed BioSphere Nanotechnology, also known as Mini-CAR. This technology emulates the functions of immune cells like T cells, NK cells, or macrophages, offering a highly targeted and safe therapeutic agent. Mini-CARs are designed to address the limitations of conventional CAR whole cell therapies, including solid tumor cancers and hereditary diseases. The company's business model includes developing its own pipeline of Mini-CAR drugs and out-licensing its platform technology to other biotech companies. Caravan Biologix leverages AI for CAR design and aims to enhance efficacy, accessibility, and safety, such as by eliminating Cytokine Release Syndrome (CRS). The company is based in Greenwood Village, CO.